MedPath

Maria Sklodowska-Curie National Research Institute of Oncology

🇵🇱Poland
Ownership
Private
Established
1951-01-01
Employees
-
Market Cap
-
Website
https://www.pib-nio.pl/

Clinical Trials

62

Active:3
Completed:18

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:3
Phase 2:18
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (54 trials with phase data)• Click on a phase to view related trials

Not Applicable
22 (40.7%)
Phase 2
18 (33.3%)
Phase 3
8 (14.8%)
Phase 1
3 (5.6%)
Phase 4
2 (3.7%)
Early Phase 1
1 (1.9%)

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

Phase 2
Not yet recruiting
Conditions
Triple Negative Breast Cancer
Uterine Cervical Cancer
Uterine Corpus Cancer
Malignant Melanoma
Clear Cell Renal Cell Carcinoma
First Posted Date
2025-05-16
Last Posted Date
2025-05-16
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
60
Registration Number
NCT06976021

Functional Abdominal Wall Reconstruction

Active, not recruiting
Conditions
Prune Belly Syndrome
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
7
Registration Number
NCT06928974
Locations
🇵🇱

Maria Sklodowska Curie Memorial National Cancer Center, Gliwice, Poland

Stereotactic Radiosurgery in the Treatment of Essential Tremor

Phase 2
Recruiting
Conditions
Essential Tremor
First Posted Date
2025-02-12
Last Posted Date
2025-02-12
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
42
Registration Number
NCT06821906
Locations
🇵🇱

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

Phase 2
Recruiting
Conditions
Breast Cancer
Interventions
Radiation: Preoperative radiation therapy
Drug: Placebo
First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
78
Registration Number
NCT06472583
Locations
🇵🇱

Maria Sklodowska-Curie National Research Institute of Oncology , Gliwice Branch, Gliwice, Poland

Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

Not Applicable
Recruiting
Conditions
Head and Neck Cancer
First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
80
Registration Number
NCT06472570
Locations
🇵🇱

1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch,, Gliwice, Gliwicw, Poland

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 13
  • Next

News

Nemtabrutinib Shows Promise in Relapsed/Refractory Follicular Lymphoma

Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial.

© Copyright 2025. All Rights Reserved by MedPath